- Home
- IBRX vs AVDX Comparison
IBRX vs AVDX Comparison
Compare IBRX & AVDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- AVDX
- Stock Information
- Founded
- IBRX 2014
- AVDX 2000
- Country
- IBRX United States
- AVDX United States
- Employees
- IBRX N/A
- AVDX N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- AVDX EDP Services
- Sector
- IBRX Health Care
- AVDX Technology
- Exchange
- IBRX Nasdaq
- AVDX Nasdaq
- Market Cap
- IBRX 2.3B
- AVDX 2.0B
- IPO Year
- IBRX N/A
- AVDX 2021
- Fundamental
- Price
- IBRX $2.81
- AVDX $9.84
- Analyst Decision
- IBRX Strong Buy
- AVDX Hold
- Analyst Count
- IBRX 5
- AVDX 15
- Target Price
- IBRX $11.40
- AVDX $10.04
- AVG Volume (30 Days)
- IBRX 7.3M
- AVDX 2.5M
- Earning Date
- IBRX 08-11-2025
- AVDX 07-30-2025
- Dividend Yield
- IBRX N/A
- AVDX N/A
- EPS Growth
- IBRX N/A
- AVDX N/A
- EPS
- IBRX N/A
- AVDX 0.01
- Revenue
- IBRX $31,222,000.00
- AVDX $441,284,000.00
- Revenue This Year
- IBRX $567.98
- AVDX $5.63
- Revenue Next Year
- IBRX $160.56
- AVDX $9.83
- P/E Ratio
- IBRX N/A
- AVDX $1,101.12
- Revenue Growth
- IBRX 10238.41
- AVDX 10.46
- 52 Week Low
- IBRX $1.83
- AVDX $6.61
- 52 Week High
- IBRX $7.48
- AVDX $12.93
- Technical
- Relative Strength Index (RSI)
- IBRX 51.33
- AVDX 68.79
- Support Level
- IBRX $2.68
- AVDX $9.83
- Resistance Level
- IBRX $3.00
- AVDX $9.81
- Average True Range (ATR)
- IBRX 0.16
- AVDX 0.02
- MACD
- IBRX -0.00
- AVDX -0.02
- Stochastic Oscillator
- IBRX 62.00
- AVDX 81.25
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About AVDX AvidXchange Holdings Inc.
AvidXchange Holdings Inc is a provider of AP automation software and payment solutions for middle-market businesses and their suppliers. It generates the majority of its sales from Payment revenue followed by Software revenue and Services revenue. The company generates revenue in the United States.